Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 28, Issue 2, 2010, Pages 238-245

  Martín Mola, Emilio ^a   Sieper, Joachim ^b   Leirisalo Repo, Marjatta ^c   Dijkmans, Ben A C ^d,e   Vlahos, Bonnie ^f   Pedersen, Ronald ^f   Koenig, Andrew S ^f   Freundlich, Bruce ^e  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e JAN VAN BREEMEN INSTITUTE   (Netherlands)

^f PFIZER INC   (United States)

Author keywords

Anti TNF; Etanercept; Physical function; Spondyloarthritis

Indexed keywords

ETANERCEPT; PLACEBO;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERTENSION; INJECTION SITE REACTION; IRIDOCYCLITIS; IRITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PHYSICAL MOBILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SPINE MOBILITY; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VAGINITIS;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PATIENT SATISFACTION; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 77952781795     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ankylosing Spondylitis: Diagnosis and Management. VAN ROYEN BJ, DIJKMANS BAC (Eds.) New York, London: Taylor & Francis; 2006.
2. TOUSSIROT E, LAFFORGUE P, BOUCRAUT J et al.: Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994; 13: 175-180
3. GRATACOS J, COLLADO A, FILELLA X et al.: Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927-931
4. BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
5. GROM AA, MURRAY KJ, LUYRINK L et al.: Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703-1710
6. CANETE JD, LLENA J, COLLADO A et al.: Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997; 36: 38-42.
7. BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-1675
8. DAVIS JCJ, VAN DER HEIJDE D, BRAUN J et al.: Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2003; 48: 3230-3236
9. CALIN A, DIJKMANS BA, EMERY P et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-1600
10. GORMAN JD, SACK KE, DAVIS JC JR: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-1356
11. BRAUN J, KALDEN JR: Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S164-S7.
12. BRAUN J, SIEPER J: Treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S146-S7.
13. DAVIS JC, VAN DER HEIJDE D, DOUGADOS M, WOOLLEY JM: Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005; 53: 494-501.
14. BRAUN J, MCHUGH N, SINGH A, WAJDULA JS, SATO R: Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007; 46: 999-1004.
15. DAVIS JC JR, VAN DER HEIJDE D, BRAUN J et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-3236
16. DIJKMANS B, EMERY P, HAKALA M et al.: Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009; 36: 1256-1264
17. DAVIS JC JR, VAN DER HEIJDE DM, BRAUN J et al.: Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008; 67: 346-352
18. ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-1886
19. BROPHY S, PAVY S, LEWIS P et al.: Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol 2001; 28: 2667-2673
20. BRAUN J, BARALIAKOS X, LISTING J et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57: 639-647
21. WARD MM, REVEILLE JD, LEARCH TJ, DAVIS JC JR, WEISMAN MH: Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 2008; 59: 822-832
22. WARD MM, REVEILLE JD, LEARCH TJ, DAVIS JC JR, WEISMAN MH: Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 2008; 59: 497-503.
23. WARD MM, WEISMAN MH, DAVIS JC JR, REVEILLE JD: Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005; 53: 710-717
24. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-452